Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution

May 2021, Cancer Immunology and Immunotherapy 70(5):1-11
(DOI:10.1007/s00262-020-02751-0)